Sangamo reports $257.8M net loss for FY2023; cash runway into Q3 2024

SANGAMO THERAPEUTICS, INC

Net loss $257.8M ($1.48/share) on revenue $176.2M (up 58% YoY on Biogen termination).
Cash $81.0M as of Dec 31, 2023; expects funding into Q3 2024 without additional capital.
STAC-BBB capsid showed 700-fold higher brain transduction vs AAV9 in NHPs; pain IND Q4 2024.
Fabry drug aligned with FDA on abbreviated approval pathway; EMA PRIME granted; seeking partner.
Wind down of French ops (93 roles); 2024 GAAP opex guidance $145–165M.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

SANGAMO THERAPEUTICS, INC reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On March 13, 2024, Sangamo Therapeutics, Inc. (“Sangamo”) issued a press release announcing its financial results for the year ended December 31, 2023 (the “Press Release”).

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SANGAMO THERAPEUTICS, INC filing history →

Source: SEC EDGAR

accession 0001628280-24-010790

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.